Loading...

Buy Full Version
"Psoriatic Arthritis Treatment Market"

Let us help you !

Invalid Name.

Invalid Email.

Please Select Country.

Invalid contact no.

Special Symbols Not Allowed.

Invalid Security Code.

Thank You For Your Interest.

We've Successfully Got Your Message,

Our Executive will get back to you Shortly.

Psoriatic Arthritis Treatment Market by Drug Type (NSAIDs, DMARDs, Biologics, and Others), Type (Prescription, and OTC), and Route of Administration (Topical, Oral, and Injectable): Global Opportunity Analysis and Industry Forecast, 2019–2026

A05951
Pages: 228
Jan 2020 | 340 Views
 
Author(s) : Sayali Shinde , Onkar Sumant
Tables: 114
Charts: 44
 

Psoriatic Arthritis Treatment Market Overview:

The psoriatic arthritis treatment market size was valued at $7,860 million in 2018, and is estimated to reach at $13,744 million by 2026, registering a CAGR of 7.2% from 2019 to 2026. 

Psoriatic arthritis is an inflammatory joint disease associated with psoriasis, which is categorized within the group of spondyloarthritis. It affects both the skin and musculoskeletal system. It is caused due to genetic and environmental factors. Swollen toes, fingers, and tender joints, lowered back pain, pitted nails, and stiffness are prevalent symptoms of psoriatic arthritis. Diagnosis of psoriatic arthritis is done by tests such as joint fluid test, X-ray, rheumatoid factor (RF), and magnetic resonance imaging (MRI). Psoriatic arthritis can be treated with drug class such as NSAIDs, disease-modifying antirheumatic drugs (DMARDs), biologics, and immunosuppressant drugs.

Psoriatic Arthritis Treatment Market

Get more information on this report : Request Sample Pages

Rise in biological and biosimilar therapies, increase in prevalence of psoriatic arthritis, surge in R&D activities to develop novel drugs for the treatment of psoriatic arthritis, rise in demand for psoriatic arthritis treatment products, surge in geriatric population, strong pipeline of biosimilar & biologic products, and rise in awareness toward psoriatic arthritis treatment are the major factors that drive the growth of the global psoriatic arthritis treatment market. In addition, increase in adoption of psoriatic arthritis treatment drugs, presence of large patient pool, availability of patient assistance programs, and rise in healthcare expenditure are other factors that contribute toward the growth of the market. However, high cost of treatment and lack of standardization tools for diagnosis are expected to hinder the market growth. On the contrary, untapped potential offered by developing economies are expected to present lucrative opportunities for market expansion during the forecast period.

Psoriatic Arthritis Treatment Market Segmentation  

The global psoriatic arthritis treatment market is segmented into drug type, type, route of administration, and region. By drug type, the market is categorized into NSAIDs, DMARDs, biologics, and others. On the basis of type, the market is divided into prescription, and OTC. According to route of administration, the market is segregated into topical, oral, and injectable. Region wise, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).  

Segment Review 

Depending on drug type, presently, the biologics segment dominates the global psoriatic arthritis treatment market, and is anticipated to continue this trend during the forecast period. This is attributed to increase in demand & higher acceptability for innovative therapies, surge in adoption of biological therapies, and availability of generic biologic drugs. Moreover, rise in incidence of psoriatic arthritis, increase in biologics in pipeline, and advancements in biologics coupled with minimal health side effects have boosted the psoriatic arthritis treatment market growth.  

Psoriatic Arthritis Treatment Market
By Drug Type

Your browser does not support the canvas element.

Biologics is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

According to route of administration, the injectable segment generated the highest revenue in 2018, and is expected to maintain its dominance throughout the forecast period. This is attributed to surge in R&D to develop novel drugs, increase in awareness toward psoriatic arthritis treatment, rise in healthcare budgets of developed & developing countries, increase in consumption of injectable psoriatic arthritis treatment drugs, and reimbursement available for injectable drugs.

Psoriatic Arthritis Treatment Market
By Type

Your browser does not support the canvas element.

Prescription holds a dominant position in 2018 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Snapshot of Asia-Pacific Psoriatic Arthritis Treatment Market  

Asia-Pacific presents lucrative opportunities for the key players operating in the psoriatic arthritis treatment market, owing to increase in awareness toward psoriatic arthritis treatment and rise in adoption of psoriatic arthritis treatment products. Moreover, improvement in healthcare infrastructure, rise in number of hospitals equipped with advanced medical facilities, development of the R&D sector, rise in healthcare reforms, and technological advancements in the field of healthcare are expected to significantly contribute toward the market growth. The other factors such as surge in focus of leading manufacturers on expanding their geographical presence in emerging Asia-Pacific countries to capture high growth opportunities, and presence of large population base are expected to drive the growth of the psoriatic arthritis treatment market in Asia-Pacific.

   

Psoriatic Arthritis Treatment Market
By Geography

2026
North America 
Europe
Asia-Pacific
LAMEA

Asia-Pacific region would exhibit the highest CAGR of 9.1% during 2019-2026.

Get more information on this report : Request Sample Pages

The key players profiled in this report include AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly And Company, Johnson & Johnson, Merck & Co Inc., Novartis AG, Pfizer Inc., and UCB S.A. 

Key Benefits for Stakeholders:

  • The study provides an in-depth analysis along with the current psoriatic arthritis treatment market trends and future estimations to elucidate the imminent investment pockets.
  • It offers psoriatic arthritis treatment market analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of four major regions is provided to determine the prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook and global psoriatic arthritis treatment market growth.

Key Market Segments:

By Drug Type 

  • NSAIDs 
  • DMARDs 
  • Biologics
  • Others 

By Type 

  • Prescription 
  • OTC 

By Route of Administration 

  • Topical
  • Oral
  • Injectable

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
 

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Porter’s five force analysis
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Rise in prevalence of psoriasis & psoriatic arthritis disease
3.4.1.2. Increase in number of pipeline drugs
3.4.1.3. Increase in government expenditure on healthcare

3.4.2. Restraint

3.4.2.1. Poor demand in under developed countries

3.4.3. Opportunities

3.4.3.1. Growth opportunities in emerging markets

3.4.4. Impact analysis

CHAPTER 4: PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE

4.1. Overview

4.1.1. Market size and forecast

4.2. NSAIDs

4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country

4.3. DMARDs

4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country

4.4. Biologics

4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country

4.5. Others

4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country

CHAPTER 5: PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE

5.1. Overview

5.1.1. Market size and forecast

5.2. Prescription

5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country

5.3. OTC

5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country

CHAPTER 6: PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

6.1. Overview

6.1.1. Market size and forecast

6.2. Injectable

6.2.1. Market size and forecast, by region
6.2.2. Market analysis, by country

6.3. Oral

6.3.1. Market size and forecast, by region
6.3.2. Market analysis, by country

6.4. Topical

6.4.1. Market size and forecast, by region
6.4.2. Market analysis, by country

CHAPTER 7: PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION

7.1. Overview

7.1.1. Market size and forecast

7.2. North America

7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country

7.2.2.1. U.S.

7.2.2.1.1. U.S. psoriatic arthritis treatment market, by drug type
7.2.2.1.2. U.S. psoriatic arthritis treatment market, by type
7.2.2.1.3. U.S. psoriatic arthritis treatment market, by route of administration

7.2.2.2. Canada

7.2.2.2.1. Canada psoriatic arthritis treatment market, by drug type
7.2.2.2.2. Canada psoriatic arthritis treatment market, by type
7.2.2.2.3. Canada psoriatic arthritis treatment market, by route of administration

7.2.2.3. Mexico

7.2.2.3.1. Mexico psoriatic arthritis treatment market, by drug type
7.2.2.3.2. Mexico psoriatic arthritis treatment market, by type
7.2.2.3.3. Mexico psoriatic arthritis treatment market, by route of administration

7.2.3. North America market size and forecast, by drug type
7.2.4. North America market size and forecast, by type
7.2.5. North America market size and forecast, by route of administration

7.3. Europe

7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country

7.3.2.1. Germany

7.3.2.1.1. Germany psoriatic arthritis treatment market, by drug type
7.3.2.1.2. Germany psoriatic arthritis treatment market, by type
7.3.2.1.3. Germany psoriatic arthritis treatment market, by route of administration7.3.2.2. France
7.3.2.2.1. France psoriatic arthritis treatment market, by drug type
7.3.2.2.2. France psoriatic arthritis treatment market, by type
7.3.2.2.3. France psoriatic arthritis treatment market, by route of administration

7.3.2.3. UK

7.3.2.3.1. UK psoriatic arthritis treatment market, by drug type
7.3.2.3.2. UK psoriatic arthritis treatment market, by type
7.3.2.3.3. UK psoriatic arthritis treatment market, by route of administration

7.3.2.4. Italy

7.3.2.4.1. Italy psoriatic arthritis treatment market, by drug type
7.3.2.4.2. Italy psoriatic arthritis treatment market, by type
7.3.2.4.3. Italy psoriatic arthritis treatment market, by route of administration

7.3.2.5. Spain

7.3.2.5.1. Spain psoriatic arthritis treatment market, by drug type
7.3.2.5.2. Spain psoriatic arthritis treatment market, by type
7.3.2.5.3. Spain psoriatic arthritis treatment market, by route of administration

7.3.2.6. Rest of Europe

7.3.2.6.1. Rest of Europe psoriatic arthritis treatment market, by drug type
7.3.2.6.2. Rest of Europe psoriatic arthritis treatment market, by type
7.3.2.6.3. Rest of Europe psoriatic arthritis treatment market, by route of administration

7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe market size and forecast, by type
7.3.5. Europe market size and forecast, by route of administration

7.4. Asia-Pacific

7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country

7.4.2.1. Japan

7.4.2.1.1. Japan psoriatic arthritis treatment market, by drug type
7.4.2.1.2. Japan psoriatic arthritis treatment market, by type
7.4.2.1.3. Japan psoriatic arthritis treatment market, by route of administration

7.4.2.2. China

7.4.2.2.1. China psoriatic arthritis treatment market, by drug type
7.4.2.2.2. China psoriatic arthritis treatment market, by type
7.4.2.2.3. China psoriatic arthritis treatment market, by route of administration

7.4.2.3. Australia

7.4.2.3.1. Australia psoriatic arthritis treatment market, by drug type
7.4.2.3.2. Australia psoriatic arthritis treatment market, by type
7.4.2.3.3. Australia psoriatic arthritis treatment market, by route of administration

7.4.2.4. India

7.4.2.4.1. India psoriatic arthritis treatment market, by drug type
7.4.2.4.2. India psoriatic arthritis treatment market, by type
7.4.2.4.3. India psoriatic arthritis treatment market, by route of administration

7.4.2.5. South Korea

7.4.2.5.1. South Korea psoriatic arthritis treatment market, by drug type
7.4.2.5.2. South Korea psoriatic arthritis treatment market, by type
7.4.2.5.3. South Korea psoriatic arthritis treatment market, by route of administration

7.4.2.6. Rest of Asia-Pacific

7.4.2.6.1. Rest of Asia-Pacific psoriatic arthritis treatment market, by drug type
7.4.2.6.2. Rest of Asia-Pacific psoriatic arthritis treatment market, by type
7.4.2.6.3. Rest of Asia-Pacific psoriatic arthritis treatment market, by route of administration

7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific market size and forecast, by type
7.4.5. Asia-Pacific market size and forecast, by route of administration

7.5. LAMEA

7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country

7.5.2.1. Brazil

7.5.2.1.1. Brazil psoriatic arthritis treatment market, by drug type
7.5.2.1.2. Brazil psoriatic arthritis treatment market, by type
7.5.2.1.3. Brazil psoriatic arthritis treatment market, by route of administration

7.5.2.2. Saudi Arabia

7.5.2.2.1. Saudi Arabia psoriatic arthritis treatment market, by drug type
7.5.2.2.2. Saudi Arabia psoriatic arthritis treatment market, by type
7.5.2.2.3. Saudi Arabia psoriatic arthritis treatment market, by route of administration

7.5.2.3. South Africa

7.5.2.3.1. South Africa psoriatic arthritis treatment market, by drug type
7.5.2.3.2. South Africa psoriatic arthritis treatment market, by type
7.5.2.3.3. South Africa psoriatic arthritis treatment market, by route of administration

7.5.2.4. Rest of LAMEA

7.5.2.4.1. Rest of LAMEA psoriatic arthritis treatment market, by drug type
7.5.2.4.2. Rest of LAMEA psoriatic arthritis treatment market, by type
7.5.2.4.3. Rest of LAMEA psoriatic arthritis treatment market, by route of administration

7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA market size and forecast, by type
7.5.5. LAMEA market size and forecast, by route of administration

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.1.6. Key strategic moves and developments

8.2. Amgen Inc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Bristol-Myers Squibb Company

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.3.6. Key strategic moves and developments

8.4. Eli Lilly And Company.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments

8.5. Johnson & Johnson.

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Business performance
8.5.6. Key strategic moves and developments

8.6. Merck & Co Inc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance

8.7. Mylan N.V

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance

8.8. Novartis AG

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance

8.9. Pfizer Inc.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance

8.10. UCB S.A.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance

LIST OF TABLES

TABLE 01. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 02. NSAIDS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. DMARDS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. BIOLOGICS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 07. PRESCRIPTION PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTC PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026 ($MILLION)
TABLE 10. INJECTABLE PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 11. ORAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 12. TOPICAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 13. PSORIATIC ARTHRITIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 14. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 15. U.S. PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 16. U.S. PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 17. U.S. PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 18. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 19. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 20. CANADA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 21. MEXICO PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 22. MEXICO PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 23. MEXICO PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 24. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 25. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 26. NORTH AMERICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 27. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 28. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 29. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 30. GERMANY PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 31. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 32. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 33. FRANCE PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 34. UK PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 35. UK PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 36. UK PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 37. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 38. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 39. ITALY PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 40. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 41. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 42. SPAIN PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 43. REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 44. REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 45. REST OF EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 46. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 47. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 48. EUROPE PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 49. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 50. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 51. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 52. JAPAN PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 53. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 54. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 55. CHINA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 56. AUSTRALIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 57. AUSTRALIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 58. AUSTRALIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 59. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 60. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 61. INDIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 62. SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 63. SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 64. SOUTH KOREA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 65. REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 66. REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 67. REST OF ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 68. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 69. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 70. ASIA-PACIFIC PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 71. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 72. BRAZIL PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 73. BRAZIL PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 74. BRAZIL PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 75. SAUDI ARABIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 76. SAUDI ARABIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 77. SAUDI ARABIA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 78. SOUTH AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 79. SOUTH AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 80. SOUTH AFRICA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 81. REST OF LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 82. REST OF LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 83. REST OF LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 84. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 85. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 86. LAMEA PSORIATIC ARTHRITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018–2026
TABLE 87. ABBVIE INC: COMPANY SNAPSHOT
TABLE 88. ABBVIE INC: OPERATING SEGMENTS
TABLE 89. ABBVIE INC: PRODUCT PORTFOLIO
TABLE 90. AMGEN: COMPANY SNAPSHOT
TABLE 91. AMGEN: PRODUCT SEGMENT
TABLE 92. AMGEN: PRODUCT PORTFOLIO
TABLE 93. BMS.: OPERATING SEGMENT
TABLE 94. BMS.: PRODUCT PORTFOLIO
TABLE 95. LILLY: COMPANY SNAPSHOT
TABLE 96. LILLY: OPERATING SEGMENTS
TABLE 97. LILLY: PRODUCT PORTFOLIO
TABLE 98. J&J: COMPANY SNAPSHOT
TABLE 99. J&J: OPERATING SEGMENTS
TABLE 100. J&J: PRODUCT PORTFOLIO
TABLE 101. MERCK & CO., INC: COMPANY SNAPSHOT
TABLE 102. MERCK & CO., INC: OPERATING SEGMENTS
TABLE 103. MERCK & CO., INC: PRODUCT PORTFOLIO
TABLE 104. MYLAN: COMPANY SNAPSHOT
TABLE 105. MYLAN: OPERATING SEGMENTS
TABLE 106. MYLAN: PRODUCT PORTFOLIO
TABLE 107. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 108. NOVARTIS AG: OPERATING SEGMENTS
TABLE 109. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 110. PFIZER INC: COMPANY SNAPSHOT
TABLE 111. PFIZER INC: OPERATING SEGMENTS
TABLE 112. PFIZER INC: PRODUCT PORTFOLIO
TABLE 113. UCB S.A.: COMPANY SNAPSHOT
TABLE 114. UCB S.A.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. GLOBAL PSORIATIC ARTHRITIS TREATMENT MARKET SEGMENTATION
FIGURE 02. TOP INVESTMENT POCKETS
FIGURE 03. HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 04. MODERATE BARGAINING POWER OF BUYERS
FIGURE 05. HIGH THREAT OF SUBSTITUTES
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. HIGH INTENSITY OF RIVALRY
FIGURE 08. IMPACT ANALYSIS
FIGURE 09. COMPARATIVE ANALYSIS OF NSAIDS PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 10. COMPARATIVE ANALYSIS OF DMARDS PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 11. COMPARATIVE ANALYSIS OF BIOLOGICS PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 12. COMPARATIVE ANALYSIS OF OTHERS PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 13. COMPARATIVE ANALYSIS OF PRESCRIPTION PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 14. COMPARATIVE ANALYSIS OF OTC PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 15. COMPARATIVE ANALYSIS OF INJECTABLE PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 16. COMPARATIVE ANALYSIS OF ORAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 17. COMPARATIVE ANALYSIS OF TOPICAL PSORIATIC ARTHRITIS TREATMENT MARKET, BY COUNTRY, 2018 & 2026 ($MILLION)
FIGURE 18. ABBVIE INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 19. ABBVIE INC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 20. ABBVIE INC: REVENUE SHARE BY REGION, 2018(%)
FIGURE 21. AMGEN: NET SALES, 2016–2018 ($MILLION)
FIGURE 22. AMGEN: REVENUE SHARE BY REGION, 2018(%)
FIGURE 23. BMS: NET SALES, 2016–2018 ($MILLION)
FIGURE 24. BMS: REVENUE SHARE BY REGION, 2018(%)
FIGURE 25. LILLY: NET SALES, 2016–2018 ($MILLION)
FIGURE 26. LILLY: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 27. LILLY: REVENUE SHARE BY REGION, 2018(%)
FIGURE 28. J&J: NET SALES, 2016–2018 ($MILLION)
FIGURE 29. J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 30. J&J: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 31. MERCK & CO., INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 32. MERCK & CO., INC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 33. MERCK & CO., INC: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 34. MYLAN: NET SALES, 2016–2018 ($MILLION)
FIGURE 35. MYLAN: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 36. NOVARTIS AG: NET SALES, 2016–2018 ($MILLION)
FIGURE 37. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 38. NOVARTIS AG: REVENUE SHARE BY REGION, 2018(%)
FIGURE 39. PFIZER INC: NET SALES, 2016–2018 ($MILLION)
FIGURE 40. PFIZER INC: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 41. PFIZER INC: REVENUE SHARE BY REGION, 2018(%)
FIGURE 42. UCB S.A.: NET SALES, 2016–2018 ($MILLION)
FIGURE 43. UCB S.A.: REVENUE SHARE BY SEGMENT, 2018 (%)
FIGURE 44. UCB S.A.: REVENUE SHARE BY GEOGRAPHY, 2018 (%)

 
 

Psoriatic arthritis is a form of chronic inflammatory disease, which affects the fingers and toes of the patient, and gradually affects skin and nails. The clinical symptoms of psoriatic arthritis are axial disease, enthesitis, dactylitis, and peripheral arthritis. Treatment of psoriatic arthritis can be done using different drug types such as NSAIDs, DMARDs, biologics, and others.

Increase in awareness programs toward psoriatic arthritis treatment therapies, rise in prevalence of psoriatic arthritis, stressful lifestyle resulting in the overstimulation of immune system, and surge in R&D for the innovation of new products significantly boost the growth of psoriatic arthritis treatment market. Moreover, strong pipeline of biosimilar & biologic products, rise in geriatric population, presence of large patient pool, and rise in adoption of novel treatments drive the market growth. However, high treatment costs is expected to restrain the growth of the market.

North America is expected to remain dominant during the forecast period, due to increase in prevalence of psoriatic arthritis, presence of pipeline drugs under various stages of clinical trials, and increase in patient pool suffering from psoriatic arthritis. However, Asia-Pacific is expected to offer lucrative opportunities to the key players during the forecast period, due to development of the healthcare sector along with rise in demand for psoriatic arthritis treatment products.

 

 

 

PURCHASE OPTIONS

Start reading instantly ,This title and over 12000 thousand more,available with Avenue Library, Subscription @ $699 T&C*

Reach out to us

Call us on
( U.S. - Canada toll free )
+1-800-792-5285,   
Int'l : +1-503-894-6022
( Europe )
+ 44-845-528-1300
Drop us an email at
help@alliedmarketresearch.com

Send Enquiry

Download Sample

Request Customization

FREQUENTLY ASKED QUESTIONS?
 

A. The market value of global psoriatic arthritis treatment market was $7,860.03 million in 2018.

A. The forecast period is from 2019 to 2026.

A. The market value of global psoriatic arthritis treatment market in 2019 is $8,442.5 million.

A. The adoption of psoriatic arthritis treatment is expected to increase due to significant increase in prevalence of psoriatic arthritis, rise in demand for psoriatic arthritis pharmacotherapy, strong pipeline of biosimilar & biologic products, stressful lifestyle resulting in the overstimulation of immune system, and rise in geriatric population majorly driving the market growth

A. The base year calculated in the report is 2018.

A. Yes, Eli Lilly and Company is profiled in the report.

A. Emerging countries of Asia-Pacific region are growing at a growth% of 9.1%. Japan, China, Australia, India, South Korea are expected grow at a CAGR of 9.0%, 10.1%, 8.2%, 9.8%, 8.6% respectively.

A. The North America market held a major share in the psoriatic arthritis treatment in 2018 and is expected to continue the trend in the forecasting period. This is attributed to introduction of advanced psoriatic arthritis treatment products, increase in adoption of psoriatic arthritis treatment drugs, surge in production of biologics & generics, and rise in nongovernment & government initiatives to promote healthcare are driving the psoriatic arthritis treatment market in North America

 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Sample

OR

Purchase Full Report of
Psoriatic Arthritis Treatment Market

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Single User
  • $5,370
  • Restricted to one authorized user
  • One print only
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Enterprise
    License/PDF

  • $8,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  •   Free quarterly industry update
  •   Free report update (Within 180 days)
  •   Subscription model sign in
  • Library Membership
  • $0.00
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Start reading instantly.
    This title and over 12,000+ are available on the Avenue Library. Subscription @ $699 T&C*.

    Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

 
 

Featured Reports

 

Featured Readings

 

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

 
Get Industry Data Alerts
 
Download Sample